aTyr Pharma, Inc. ATYR
0.31
(0.03)
(8.82%)
as of 25 Sep
- Market cap
- $31.4M
- P/E
- 0.0×
Follow ATYR
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(103.49%) | (108.11%) | (105.62%) | (98.67%) | |
| (75.78%) | (78.09%) | (79.17%) | (70.97%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(91.88%) | (106.87%) | (116.49%) | (119.01%) | |
Average Days of Receivables |
34.07 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.65) | (0.67) | (0.60) | (0.56) | |
Free Cash Flow |
(63.00) | (62.07) | (59.29) | (54.81) | |
Capital Expenditures |
(0.08) | (0.08) | (0.20) | (0.27) | |
Piotroski F-Score |
4.00 | — | — | — | |
| Other line items | |||||
Cash ROIC |
(36.87%) | (42.39%) | (47.49%) | (51.43%) | |
Accounts Receivable Turnover |
7.77 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
551.38% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
154.83% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
40.85% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.84 | 0.84 | 0.84 | 0.90 | |
Depreciation/Fixed assets |
(0.20) | (0.07) | (0.01) | 0.07 | |
Capex/Depreciation |
0.09 | 0.28 | 9.23 | (0.87) | |
Revenue per Share |
0.11 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.65) | (0.67) | (0.60) | (0.56) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(672.90%) | 0.00% | 0.00% | 0.00% |
Columns are period end dates